scholarly journals Real-World Evidence and Advanced Soft Tissue Sarcoma: An Unbreakable Bond (ESMO Sarcoma and GIST Symposium 2020 Industry Satellite Symposium, Milan, February 4, 2020)

Oncology ◽  
2021 ◽  
Vol 99 (Suppl. 1) ◽  
pp. 1-2
Author(s):  
George D. Demetri
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Real World ◽  
Satellite Symposium ◽  
Advanced Soft Tissue Sarcoma ◽  
Real World Evidence

Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma

2020 ◽  
Vol 20 (11) ◽  
pp. 957-963
Author(s):  
Luis Miguel de Sande González ◽  
Javier Martin-Broto ◽  
Bernd Kasper ◽  
Jean-Yves Blay ◽  
Axel Le Cesne
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Real World ◽  
Advanced Soft Tissue Sarcoma ◽  
Real World Evidence

scholarly journals 1657P Pazopanib treatment outcome in advanced soft tissue sarcoma: Real-world data

2020 ◽  
Vol 31 ◽  
pp. S987
Author(s):  
B. Alshamsan ◽  
A. Alshibany ◽  
A. Badran ◽  
F. Maraiki ◽  
M.A. Elshenawy ◽  
...  
Keyword(s):  
Treatment Outcome ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Real World ◽  
Real World Data ◽  
Advanced Soft Tissue Sarcoma ◽  
World Data

scholarly journals Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma

2021 ◽  
Vol Volume 13 ◽  
pp. 6755-6766
Author(s):  
Bader Alshamsan ◽  
Ahmad Badran ◽  
Aisha Alshibany ◽  
Fatma Maraiki ◽  
Mahmoud A Elshenawy ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Real World ◽  
Advanced Soft Tissue Sarcoma

scholarly journals Treatment Patterns and Survival among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France

Sarcoma ◽  
2018 ◽  
Vol 2018 ◽  
pp. 1-12 ◽  
Author(s):  
Saurabh P. Nagar ◽  
Daniel S. Mytelka ◽  
Sean D. Candrilli ◽  
Yulia D’yachkova ◽  
Maria Lorenzo ◽  
...  
Keyword(s):  
Overall Survival ◽  
United Kingdom ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Medical Record ◽  
Real World ◽  
Treatment Patterns ◽  
Adult Patients ◽  
Advanced Soft Tissue Sarcoma ◽  
The United Kingdom

Objective. To describe real-world treatment patterns and outcomes for patients with advanced soft tissue sarcoma (STS) not amenable to surgery or radiotherapy in the United Kingdom, Spain, Germany, and France. Methods. Physicians completed a web-based medical record abstraction for adult patients with advanced STS (other than Kaposi’s sarcoma or gastrointestinal stromal tumor) who received ≥1 line of systemic therapy. Clinical characteristics, treatments, tumor responses, and mortality data were recorded. Results. A total of 130 physicians provided data for 807 patients. Patients’ mean age at advanced STS diagnosis was 57.1 (±12.3) years; 59% were male. The most commonly identified histologic categories were leiomyosarcoma (28%), liposarcoma (13%), and rhabdomyosarcoma (11%). Overall, 57% of patients received only 1 line of therapy, 32% received 2 lines of therapy, and 11% received ≥3 lines of therapy. The most common first-line regimens were doxorubicin alone (41%), doxorubicin plus ifosfamide (19%), docetaxel plus gemcitabine (9%), paclitaxel alone (4%), and ifosfamide (4%). Median overall survival from start of treatment was estimated to be 17.6 months (95% confidence interval, 15.6–19.0 months). Conclusions. In real-world clinical practice, advanced STS is most commonly treated with older therapies in the United Kingdom, Spain, Germany, and France. New therapies that improve overall survival in advanced STS are needed.

scholarly journals PCN500 REAL-WORLD TREATMENT PATTERNS AND OUTCOMES FOR PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA RECEIVING SYSTEMIC THERAPY IN BRAZIL

2019 ◽  
Vol 22 ◽  
pp. S534-S535
Author(s):  
A.C. Melo ◽  
P.X. Santi ◽  
D.L. Nunes ◽  
S.B. Aleixo ◽  
C.L. Martins ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Real World ◽  
Systemic Therapy ◽  
Treatment Patterns ◽  
Advanced Soft Tissue Sarcoma

Real-world experience of Olaratumab and Doxorubicin versus Doxorubicin alone for advanced soft-tissue sarcoma in a UK centre

2019 ◽  
Vol 31 ◽  
pp. e9
Author(s):  
Ian S. Boon ◽  
Laura Jaques ◽  
Leanne Elder ◽  
Margaret Purkis ◽  
Jason Wong ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Real World ◽  
Advanced Soft Tissue Sarcoma

scholarly journals Real-World Outcomes of Advanced Soft Tissue Sarcoma Patients Treated with Pazopanib

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Fawaz A ◽  
◽  
Shim I ◽  
Tilley D ◽  
Kelaney MR ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Overall Survival ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Real World ◽  
Systemic Therapy ◽  
Kinase Inhibitor ◽  
Advanced Soft Tissue Sarcoma ◽  
Clinical Trial Setting ◽  
Trial Setting

Background: Pazopanib is an oral multitarget tyrosine kinase inhibitor that is currently approved for the treatment of select subtypes of advanced Soft Tissue Sarcoma (STS) in patients who have progressed on prior anthracyclinebased chemotherapy regimens. In this study, we examine data from multiple centers to assess the efficacy of pazopanib in practice outside of a clinical trial setting. Methods: A retrospective chart analysis was conducted for pre-treated, advanced soft tissue sarcoma patients who began treatment with pazopanib in Alberta, Canada and Cairo, Egypt (2012-2018). Results: In total, 39 predominantly male (56.4%) patients received pazopanib. The median age was 51, 67% of whom had an ECOG of one or less. The predominant sarcoma subtype was leiomyosarcoma (30.8%), and all patients had received at least one prior line of systemic therapy. Thirtytwo of the 39 patients (82%) were initially given the full dose of 800mg with a median time on treatment of 116 days. Seven of the 39 (18%) patients required a dose reduction while on treatment. A majority (94.9%) of patients ultimately discontinued pazopanib treatment for reasons including death (21.6%), disease progression (62.2%), and toxicity (16.4%). The median progression-free and overall survival for these patients was 4.1 months (95%CI, 3.6-4.5) and 8.4 months (95% CI, 4.3-12.5), respectively. Conclusion: Pazopanib is an efficient and generally well-tolerated oral systemic therapy for the treatment of advanced, pre-treated, non-adipocytic soft tissue sarcoma. These results show the efficacy of pazoponib outside of a clinical trial setting.

Sign in / Sign up

Export Citation Format

Share Document